RxDoctor Payments Data

Gregory Rucker, MD

Internal Medicine · Columbus, GANPI 1073510905

Payments from drug & device makers

$1,187in general payments, 2019–2025

Across 69 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$490
  • Lilly USA, LLC$173
  • Boehringer Ingelheim$113
  • Bayer$75
  • Astellas Pharma US Inc$66
  • Novartis$46
  • plus $224 from 10 others

What the payments were for

  • Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,187 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$66,083
Medicare patients
81
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$101,372
JanuviaSitagliptin Phosphate41$42,532
FarxigaDapagliflozin Propanediol38$28,936
JardianceEmpagliflozin33$27,462
GlyxambiEmpagliflozin/Linagliptin38$26,863
MounjaroTirzepatide16$26,580
CreonLipase/Protease/Amylase15$22,377
LinzessLinaclotide20$19,164
EliquisApixaban22$16,341
Xtampza ErOxycodone Myristate13$15,452
XareltoRivaroxaban13$14,253
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen299$10,197
Tresiba Flextouch U-100Insulin Degludec21$9,036
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen297$7,362
Trijardy XrEmpaglifloz/Linaglip/Metformin11$6,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$490$101,372101 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr$113$61,06382 claims
MerckJanuvia$42$42,53241 claims
AbbVieCreon, Linzess$40$41,54135 claims
AstraZenecaFarxiga$19$28,93638 claims
Lilly USA, LLCMounjaro$173$26,58016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →